**Executive Summary**
On May 8, 2026, the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, signed a Memorandum of Understanding (MoU), Confidential Disclosure Agreement (CDA), and Technology Transfer Agreement with Lofty Laboratories, Hyderabad. This partnership aims to promote indigenous technology commercialization within the biotechnology and pharmaceutical sectors, specifically focusing on industry-ready technology from NIPER's Center of Excellence on Novel Drug Delivery Systems. The collaboration seeks to reduce research costs and strengthen India’s pharmaceutical infrastructure, with more technologies expected to be ready for transfer by the end of the year.
**Key Points / Main Content**
**Agreement and Collaboration Framework**
* **Multidirectional Collaboration:** The signing of the MoU, CDA, and Technology Transfer Agreement establishes a framework for cooperation in research, innovation, and commercialization.
* **Academia-Industry Synergy:** The partnership is designed to enable both institutions to complement their respective research programs through joint participation in R&D.
**Technology Transfer and Commercialization**
* **Industry-Ready Technology:** Lofty Laboratories will adopt and commercialize specific technology developed at NIPER-Raebareli.
* **Center of Excellence (CoE) Involvement:** Collaborative activities will involve the Institute’s Center of Excellence on Novel Drug Delivery Systems (CoE-NDDS).
* **Future Pipeline:** The Institute anticipates that several additional technologies will be prepared for transfer to industry partners by the end of 2026.
**Product Innovation and Economic Impact**
* **Gel-Staining Agents:** The current technology transfer focuses on novel gel-staining agents used globally in gene, cancer, and nucleic acid-related research.
* **Cost Reduction:** Commercialization of this technology is expected to significantly lower the cost of these agents compared to existing options.
* **Indigenous Production:** The initiative promotes the domestic production of research materials to strengthen India’s pharmaceutical and biotechnology sectors.
**Impact Analysis**
**NIPER Raebareli**
**Impact**
The institute transitions its academic research into practical, industry-ready applications, enhancing the profile of its Center of Excellence on Novel Drug Delivery Systems.
**Action Required**
The institute must continue collaborative participation in R&D activities and prepare the next batch of technologies for transfer by the end of the year.
**Lofty Laboratories, Hyderabad**
**Impact**
The company gains access to indigenous, industry-ready biotechnology for commercial development and market distribution.
**Action Required**
The laboratory is required to adopt the transferred technology and proceed with its further development and commercialization.
**Biotechnology and Pharmaceutical Research Sector**
**Impact**
Researchers in these fields will benefit from the availability of more affordable, indigenously produced gel-staining agents for studies on genes and cancer.
**Action Required**
Stakeholders in this sector should prepare to integrate these cost-effective indigenous agents into their research and development workflows.
Key Entities Referenced
National Institute of Pharmaceutical Education and Research (NIPER), Raebareli: An academic institution under the Department of Pharmaceuticals that developed the indigenous technology and entered into a commercialization partnership.
Lofty Laboratories, Hyderabad: The industry partner responsible for the commercialization and further development of technologies transferred from NIPER-Raebareli.
Center of Excellence on Novel Drug Delivery Systems (CoE-NDDS): A specialized research unit at NIPER-Raebareli focused on innovative drug delivery systems and the development of cost-effective gel-staining agents.
Technology Transfer Agreement: The legal instrument signed between academia and industry to facilitate the commercial production of indigenous pharmaceutical and biotechnology research.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
NIPER Raebareli Signs MoU, CDA, and
Technology Transfer Agreement with Lofty
Laboratories
Academia-Industry Partnership to Promote Indigenous
Technology Commercialization in Biotechnology Sector
Posted On: 08 MAY 2026 3:20PM by PIB Delhi
National Institute of Pharmaceutical Education and Research (NIPER), Raebareli has signed a
Memorandum of Understanding (MoU), Confidential Disclosure Agreement (CDA), and Technology
Transfer Agreement with Lofty Laboratories, Hyderabad to foster multidirectional collaboration in
research, innovation, and technology commercialization.
This MoU marks a significant step towards strengthening academia-industry partnerships aimed at
advancing pharmaceutical and biotechnology research. During the signing ceremony, both the
organizations agreed to adopt an industry-ready technology developed at NIPER-Raebareli for further
commercialization and development. The collaboration will also include joint participation in research and
development activities in areas of mutual interest.
Speaking during the occasion, the Director of NIPER-Raebareli, Prof. Shubhini A. Saraf, stated that the
MoU and technology transfer agreement would enable both institutions to complement each other’s
research programs in multiple ways, including collaborative participation in the activities of the
Institute’s Center of Excellence on Novel Drug Delivery Systems (CoE-NDDS).Prof. Saraf also highlighted the importance of the technology developed in CoE and expressed hope that
several more technologies from the Institute would be ready for transfer by the end of the year.
Addressing the gathering, Prof. Nihar Ranjan, Head, CoE-NDDS explained that commercialization of the
present technology would significantly reduce the cost of gel-staining agents, which are extensively used
worldwide in biology-related research, particularly in studies involving genes, cancer, and other nucleic
acid-related diseases. He added that indigenous production of such novel gel-staining agents would
contribute substantially towards strengthening India’s pharmaceutical and biotechnology sectors.
*****
PC/PM
(Release ID: 2259032) Visitor Counter : 292
Read this release in: Urdu , ही , Tamil